LUMICKS Strengthens Board of Directors With Two Key Appointments finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding.
The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team.
The company intends to use the funds to accelerate growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.
LUMICKS Raises $93 Million in Series D Financing
- Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors
AMSTERDAM, April 16, 2021 /PRNewswire/ LUMICKS, a leading, next-generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing.
The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners, and included investments by Softbank Vision 2